KRMD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

10.46M

+18.36%

-0.022

+125%

11.18M

+16%

-0.015

-25%

Estimates Revision

The market is revising Upward the revenue expectations for KORU Medical Systems, Inc. (KRMD) for FY2025, with the revenue forecasts being adjusted by 1.57% over the past three months. During the same period, the stock price has changed by 31.70%.

Revenue Estimates for FY2025

Revise Upward

+1.57%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-37.5%

In Past 3 Month

Stock Price

Go Up

+31.70%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast KRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRMD is 5.00 USD with a low forecast of 4.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

4.00

Averages

5.00

High

6.00

Current: 0.000

Low

4.00

Averages

5.00

High

6.00

Lake Street

Buy

upgrade

$6 -> $8

2025-12-22

Reason

Lake Street

Price Target

$6 -> $8

2025-12-22

upgrade

Buy

Reason

Lake Street raised the firm's price target on Koru Medical to $8 from $6 and keeps a Buy rating on the shares. The firm, which thinks a 510K submission for the oncology indication prior to year-end is "a meaningful catalyst, expects 2026 to be another year of growth acceleration and improving leverage, supporting revenue upside and multiple expansion, the analyst tells investors.

Canaccord

Buy

maintain

$5 -> $6

2025-12-17

Reason

Canaccord

Price Target

$5 -> $6

2025-12-17

maintain

Buy

Reason

Canaccord raised the firm's price target on Koru Medical to $6 from $5 and keeps a Buy rating on the shares. The firm updated its model to reflect their new 2027 estimates.

Craig-Hallum

Buy

maintain

2025-11-13

Reason

Craig-Hallum

Price Target

2025-11-13

maintain

Buy

Reason

Craig-Hallum raised the firm's price target on Koru Medical to $6.25 from $6 and keeps a Buy rating on the shares following Koru's strong quarter, as international growth continues to inflect and the core U.S. SCIg business delivers above-market performance. Overall, revenue grew 27% year-over-year, surpassing expectations, and guidance was raised.

Piper Sandler

Neutral

maintain

2025-08-07

Reason

Piper Sandler

Price Target

2025-08-07

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on Koru Medical to $4 from $3.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results that beat Street, including revenue of $10.2M/+21% year-over-year as U.S./International grew 15%/34%, respectively. Management also nudged 2025 revenue guidance higher by $1M, reiterated its gross margin percentage outlook, and pointed to positive cash generation in the second half of the year. In general, a solid quarter with upside balanced across the company's three segments, although Piper would still like to see better translation of the strong top-line growth to P&L leverage.

Piper Sandler

Jason Bednar

Neutral

downgrade

2025-05-08

Reason

Piper Sandler

Jason Bednar

Price Target

2025-05-08

downgrade

Neutral

Reason

Piper Sandler analyst Jason Bednar lowered the firm's price target on Koru Medical to $3.50 from $4.50 and keeps a Neutral rating on the shares. The firm notes the company reported Q1 results that beat Street, including revenue of $9.6M/+17.5% year-over-year as U.S./International grew 16%/36%, respectively. The beat was wide enough for management to bump 2025 revenue guidance higher by $0.5M, Piper says, adding that it's encouraging to see gross margin percentage durability despite the geographic mix shift, and management also highlighted plans to submit for approval later this year for two commercialized drugs on the company's Freedom Infusion System.

Piper Sandler

Jason Bednar

Buy

Hold

Downgrades

$4.5

2025-02-14

Reason

Piper Sandler

Jason Bednar

Price Target

$4.5

2025-02-14

Downgrades

Buy

Hold

Reason

Piper Sandler analyst Jason Bednar downgraded Koru Medical to Neutral from Overweight with an unchanged price target of $4.50. The company's execution "has unquestionably improved," but the stock's valuation is sitting near multi-year highs even off potentially higher revenue numbers, the analyst tells investors in a research note. The firm says Koru's "loftier valuation" is making it "slightly more uneasy about other items," including tougher compares for the U.S. subcutaneous immunoglobulin market, its limited gross margin upside in 2025 and 2026 due to geographic mix, and novel therapies revenue catalysts that look more weighted to 2026 and beyond. As such, Piper believes other stocks offer a superior risk/reward.

Valuation Metrics

The current forward P/E ratio for KORU Medical Systems Inc (KRMD.O) is -448.80, compared to its 5-year average forward P/E of -45.52. For a more detailed relative valuation and DCF analysis to assess KORU Medical Systems Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-45.52

Current PE

-448.80

Overvalued PE

34.26

Undervalued PE

-125.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.12

Current EV/EBITDA

121.50

Overvalued EV/EBITDA

170.57

Undervalued EV/EBITDA

-142.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.69

Current PS

5.69

Overvalued PS

6.19

Undervalued PS

3.20

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KRMD News & Events

Events Timeline

No data

News

3.5

2025-12-30Newsfilter

KORU Medical Submits 510(k) for FreedomEDGE® System to Administer PHESGO®

3.5

2025-12-19NASDAQ.COM

Revvity Enhances AI-Powered Scientific Research with Signals Xynthetica

5.0

2025-12-16Newsfilter

KORU Medical Appoints Eric Schiller as CTO to Drive Innovation Strategy

People Also Watch

Frequently Asked Questions

What is KORU Medical Systems Inc (KRMD) stock price today?

The current price of KRMD is 5.65 USD — it has decreased -2.75 % in the last trading day.

What is KORU Medical Systems Inc (KRMD)'s business?

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

What is the price predicton of KRMD Stock?

What is KORU Medical Systems Inc (KRMD)'s revenue for the last quarter?

KORU Medical Systems Inc revenue for the last quarter amounts to 10.40M USD, increased 27.17 % YoY.

What is KORU Medical Systems Inc (KRMD)'s earnings per share (EPS) for the last quarter?

KORU Medical Systems Inc. EPS for the last quarter amounts to -0.02 USD, decreased -33.33 % YoY.

What changes have occurred in the market's expectations for KORU Medical Systems Inc (KRMD)'s fundamentals?

How many employees does KORU Medical Systems Inc (KRMD). have?

KORU Medical Systems Inc (KRMD) has 80 emplpoyees as of January 10 2026.

What is KORU Medical Systems Inc (KRMD) market cap?

Today KRMD has the market capitalization of 261.72M USD.